Inhibition of GPX4 promotes ferroptosis in MDA-MB-231 and HD578T triple-negative breast cancer cells in vitro and increases sensitivity to EGFR inhibitors in vivo in xenograft tumors, suggesting that dual therapy with GPX4 inhibitors may enhance the anticancer effects of the treatment of lipid-rich tumors [48]. This evidence concerns the gene GPX4 and triple-negative breast carcinoma.